Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of Madrigal Pharmaceuticals in a report released on Friday, July 31st. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2026 earnings at $0.85 EPS, FY2026 earnings at ($4.47) EPS, FY2027 earnings at $8.32 EPS, FY2028 earnings at $31.34 EPS, FY2029 earnings at $48.44 EPS and FY2030 earnings at $77.98 EPS. Get Madrigal Pharmaceuticals alerts:Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. Read MoreReceive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.